# Regeneron Pharmaceuticals, Inc. (REGN) — Q1-2017 Earnings Results

**Report date:** 2017-05-04 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q1-2017

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Misses on EPS, Stock Up 6.7%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.92 | N/A | -10.51% |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management conveyed a positive outlook on future product launches despite the EPS miss. They emphasized the importance of innovation.

**Key quotes:**

> Management expressed confidence in the long-term growth prospects of their pipeline.

> They highlighted ongoing investments in research and development.

### Guidance Changes

No guidance was provided during the earnings call.

### What It Means

Regeneron's earnings report showed a miss on EPS, yet the stock reacted positively, rising by 6.7%. Investors may be encouraged by management's focus on future growth and ongoing R&D investments. The lack of guidance might leave some uncertainty, but the overall tone suggests confidence in upcoming developments.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q1-2017_